Status:
TERMINATED
CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation
Lead Sponsor:
Biosense Webster EMEA
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The objective of this prospective multicenter randomized study is to establish the effectiveness of treatment of persistent atrial fibrillation by encircling the pulmonary veins with radiofrequency (R...
Eligibility Criteria
Inclusion
- 18-70 years
- Written informed consent
- One documented relapse of atrial fibrillation (AF) during antiarrhythmic drug therapy after an electrical cardioversion
Exclusion
- Permanent atrial fibrillation
- Patients who had tried \>1 antiarrhythmic drug (Class I or Class III).
- AF was the sole rhythm for \>6 months before the enrollment.
- Previous ablation for AF.
- AF is deemed secondary to a transient or correctable abnormality including electrolyte imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy.
- Patients who have fibrillation episodes triggered by another uniform arrhythmia (eg, atrial flutter or atrial tachycardia).
- Patients with intra-atrial thrombus, tumor, or another abnormality that precludes catheter introduction.
- Patients with Wolf-Parkinson-White syndrome.
- Patients awaiting cardiac transplantation.
- Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-III-IV or ejection fraction (EF) \<40%.
- Patients with unstable angina or acute myocardial infarction within 3 months.
- Patients with cardiac revascularization or other cardiac surgery within 6 months.
- Patients with heart disease in which corrective surgery is anticipated.
- Patients in whom appropriate vascular access is precluded.
- Pregnant women.
- A separate requirement for antiarrhythmic drug treatment, which will require an antiarrhythmic drug not previously tried for AF suppression.
- Prior atrial surgery.
- Contraindication to treatment with warfarin or other bleeding diathesis.
- Renal failure requiring dialysis.
- Hepatic failure.
- Participant in investigational clinical or device trial.
- Unwilling or unable to give informed consent.
- Inaccessible for follow-up.
- Psychological problem that might limit compliance.
- Active abuse of alcohol or other drugs which may be causative of AF.
- An implanted device (pacemaker or cardioverter-defibrillator).
- Left atrial diameter (anteroposterior) \>50 mm.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT00227344
Start Date
December 1 2004
End Date
May 1 2009
Last Update
February 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.